BACKGROUND: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin's lymphoma (B-NHL), Hodgkin's lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored. AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections. RESULTS: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder. CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.
BACKGROUND:Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin's lymphoma (B-NHL), Hodgkin's lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored. AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections. RESULTS:Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder. CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.
Authors: Alessandro Lugli; Luigi Tornillo; Martina Mirlacher; Marcel Bundi; Guido Sauter; Luigi Maria Terracciano Journal: Am J Clin Pathol Date: 2004-11 Impact factor: 2.493
Authors: M Babjuk; V Soukup; J Mares; J Dusková; Z Sedlácek; M Trková; L Pecen; J Dvorácek; T Hanus; R Kocvara; J Novák; C Povýsil Journal: Int Urol Nephrol Date: 2002 Impact factor: 2.370
Authors: Emina Torlakovic; Goran Torlakovic; Phuong L Nguyen; Richard D Brunning; Jan Delabie Journal: Am J Surg Pathol Date: 2002-10 Impact factor: 6.394
Authors: Florian B Baumann Kubetzko; Claudio Di Paolo; Charlotte Maag; Roland Meier; Beat W Schäfer; David R Betts; Rolf A Stahel; Andreas Himmelmann Journal: Carcinogenesis Date: 2004-05-20 Impact factor: 4.944
Authors: Andrew L Feldman; Mark E Law; David J Inwards; Ahmet Dogan; Rebecca F McClure; William R Macon Journal: Mod Pathol Date: 2010-01-29 Impact factor: 7.842
Authors: Stéphanie Bougel; Stéphanie Renaud; Richard Braunschweig; Dmitri Loukinov; Herbert C Morse; Fred T Bosman; Victor Lobanenkov; Jean Benhattar Journal: J Pathol Date: 2010-01 Impact factor: 7.996